Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Berry

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
The Oncologist|December 22, 2005
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapyWilliam Berry, Mario Eisenberger
Methods in Molecular Biology (Clifton, N.J.)|January 12, 2018
Utility of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Preclinical Evaluation of Therapies in CancerWilliam Berry, Daniel Croagh
BMJ Leader|May 18, 2023
What I wish I'd known: How experienced physician managers diagnose, treat and prevent disruptive behaviourChristian Goodwin, Susan Haas, William Berry
Cancers|February 1, 2018
Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic CancerWilliam Berry, Joanne Lundy, Daniel Croagh, et al.
The Journal of Urology|November 21, 2002
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancerWilliam Berry, Shaker Dakhil, Manuel Modiano, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Connective tissue growth in a mouse model of Kosaki overgrowth syndrome is limited by STAT1Jang Kim, Hae Ryong Kwon, William Berry, et al.
Redox Biology|June 8, 2018
Loss of the ubiquitin conjugating enzyme UBE2E3 induces cellular senescenceKendra S Plafker, Katarzyna Zyla, William Berry, et al.
Cancer Investigation|March 17, 2007
Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?William Berry, Maha Elkordy, Mark O'Rourke, et al.
Clinical Prostate Cancer|March 26, 2004
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 yearsTomasz M Beer, William Berry, Emily M Wersinger, et al.
Australian Journal of General Practice|February 5, 2021
Reduced melanoma referrals during COVID-19 lockdownWilliam Berry, Katrina Tan, Andrew Haydon, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
The Oncologist|December 22, 2005
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapyWilliam Berry, Mario Eisenberger
Methods in Molecular Biology (Clifton, N.J.)|January 12, 2018
Utility of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Preclinical Evaluation of Therapies in CancerWilliam Berry, Daniel Croagh
BMJ Leader|May 18, 2023
What I wish I'd known: How experienced physician managers diagnose, treat and prevent disruptive behaviourChristian Goodwin, Susan Haas, William Berry
Cancers|February 1, 2018
Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic CancerWilliam Berry, Joanne Lundy, Daniel Croagh, et al.
The Journal of Urology|November 21, 2002
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancerWilliam Berry, Shaker Dakhil, Manuel Modiano, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Connective tissue growth in a mouse model of Kosaki overgrowth syndrome is limited by STAT1Jang Kim, Hae Ryong Kwon, William Berry, et al.
Redox Biology|June 8, 2018
Loss of the ubiquitin conjugating enzyme UBE2E3 induces cellular senescenceKendra S Plafker, Katarzyna Zyla, William Berry, et al.
Cancer Investigation|March 17, 2007
Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?William Berry, Maha Elkordy, Mark O'Rourke, et al.
Clinical Prostate Cancer|March 26, 2004
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 yearsTomasz M Beer, William Berry, Emily M Wersinger, et al.
Australian Journal of General Practice|February 5, 2021
Reduced melanoma referrals during COVID-19 lockdownWilliam Berry, Katrina Tan, Andrew Haydon, et al.
Pageof 4